Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis C infection and chronic renal diseases

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Hepatitis C virus (HCV) infection and chronic renal diseases can be linked in two different ways. Some forms of renal disease are precipitated by HCV infection, while patients with end-stage renal disease are at increased risk for acquiring HCV infection. Patients with chronic HCV infection and renal disease have a poor prognosis. Most studies on treatment of HCV and renal diseases have been uncontrolled trials with small number of subjects. So, there is a lack of evidence-based recommendations and guidelines on the management of this condition. In this review, we will attempt to provide the most recent insights on HCV infection both as a extrahepatic manifestations and as a complication of end-stage renal patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1–16

    Article  PubMed  CAS  Google Scholar 

  2. Gordon SC. Extrahepatic manifestations of hepatitis C. Dig Dis 1996;14:157–168

    Article  PubMed  CAS  Google Scholar 

  3. Fabrizi F, Colucci P, Ponticelli C, et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002;22:309–318

    PubMed  CAS  Google Scholar 

  4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558–567

    Article  PubMed  Google Scholar 

  5. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65:2335–2342

    Article  PubMed  Google Scholar 

  6. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3–10

    Article  PubMed  Google Scholar 

  7. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004;20:1271–1277

    Article  PubMed  CAS  Google Scholar 

  8. USDR. US Renal Data System: Excerpts from the USDR 2006. Annual Data Report.

  9. Sansonno D, Carbone A, De Re V, et al. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 2007;46:572–578

    Article  CAS  Google Scholar 

  10. D’Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995;25:361–369

    Article  PubMed  Google Scholar 

  11. Dammacco F, Sansonno D, Piccoli C, et al. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 2000;20:143–157

    Article  PubMed  CAS  Google Scholar 

  12. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291–1300

    PubMed  CAS  Google Scholar 

  13. Vigani AG, Macedo de Oliveira A, Tozzo R, et al. The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C. J Viral Hepat 2010;18:e91–e98

    Article  PubMed  Google Scholar 

  14. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490–1495

    Article  PubMed  CAS  Google Scholar 

  15. Nagasaka A, Takahashi T, Sasaki T, et al. Cryoglobulinemia in Japanese patients with chronic hepatitis C virus infection: host genetic and virological study. J Med Virol 2001;65:52–57

    Article  PubMed  CAS  Google Scholar 

  16. Barsoum RS. Hepatitis C virus: from entry to renal injury—facts and potentials. Nephrol Dial Transplant 2007;22:1840–1848

    Article  PubMed  Google Scholar 

  17. Stokes MB. Immune complex glomerulonephritis in patients with hepatitis C. Saudi J Kidney Dis Transpl 2000;11:396–404

    PubMed  CAS  Google Scholar 

  18. Fabrizi F, Lunghi G, Messa P, et al. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008;21:813–825

    PubMed  CAS  Google Scholar 

  19. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465–470

    Article  PubMed  CAS  Google Scholar 

  20. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994;46:1700–1704

    Article  CAS  Google Scholar 

  21. Chacko EC, Surrun SK, Mubarack Sani TP, et al. Chronic viral hepatitis and chronic kidney disease. Postgrad Med J 2010;86:486–492

    Article  PubMed  Google Scholar 

  22. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618–623

    Article  PubMed  CAS  Google Scholar 

  23. Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69–82

    Article  PubMed  CAS  Google Scholar 

  24. Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003;42:631–657

    Article  PubMed  Google Scholar 

  25. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436–439

    Article  PubMed  CAS  Google Scholar 

  26. Perico N, Cattaneo D, Bikbov B, et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009;4:207–220

    Article  PubMed  CAS  Google Scholar 

  27. Ferri C, Moriconi L, Gremignai G, et al. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986;43:246–253

    Article  PubMed  CAS  Google Scholar 

  28. Singer DR, Venning MC, Lockwood CM, et al. Cryoglobulinaemia: clinical features and response to treatment. Ann Med Interne 1986;137:251–253

    CAS  Google Scholar 

  29. Frankel AH, Singer DR, Winearls CG, et al. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992;82:101–124

    PubMed  CAS  Google Scholar 

  30. De Vecchi A, Montagnino G, Pozzi C, et al. Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 1983;19:221–227

    PubMed  Google Scholar 

  31. Sinico RA, Fornasieri A, Fiorini G, et al. (1985) Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long-term follow up. Int J Artif Organs 8(Suppl 2):15–18

    Google Scholar 

  32. Bombardieri S, Ferri C, Paleologo G, et al. Prolonged plasma exchange in the treatment of renal involvement in essential mixed cryoglobulinemia. Int J Artif Organs 1983;6(Suppl 1):47–50

    PubMed  Google Scholar 

  33. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054–3061

    Article  PubMed  CAS  Google Scholar 

  34. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842–846

    Article  PubMed  CAS  Google Scholar 

  35. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006;38:2308–2310

    Article  PubMed  CAS  Google Scholar 

  36. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transp 2003;9:S63–S66

    Article  Google Scholar 

  37. Fong TL, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196–199

    PubMed  CAS  Google Scholar 

  38. Macías J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009;50:1056–1063

    Article  PubMed  CAS  Google Scholar 

  39. Bjøro K, Skaug K, Haaland T, et al. Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM 1999;92:433–441

    Article  PubMed  Google Scholar 

  40. Bestard O, Cruzado JM, Ercilla G, et al. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 2006;21:2320–2324

    Article  PubMed  Google Scholar 

  41. Bruchfeld A, Saadoun D, Cacoub P. Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia–anti-viral therapy versus rituximab. Rheumatology (Oxford) 2006;45:783–784

    Article  CAS  Google Scholar 

  42. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818–3826

    Article  PubMed  CAS  Google Scholar 

  43. Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995;44:141–147

    PubMed  CAS  Google Scholar 

  44. Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease. Nephrol Dial Transplant 2003;18:1573–1580

    Article  PubMed  CAS  Google Scholar 

  45. Lopes EP, Valente LM, Silva AE, et al. Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus. Braz J Infect Dis 2003;7:353–357

    Article  PubMed  Google Scholar 

  46. Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum 2006;54:3696–3706

    Article  PubMed  CAS  Google Scholar 

  47. Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617–623

    Article  PubMed  CAS  Google Scholar 

  48. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958–965

    Article  PubMed  CAS  Google Scholar 

  49. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982

    Article  PubMed  CAS  Google Scholar 

  50. Hadziyannis SJ, Sette H Jr, Morgan TR, PEGASYS International Study Group, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–355

    PubMed  CAS  Google Scholar 

  51. Fabrizi F, Bruchfeld A, Mangano S, et al. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007;30:212–219

    PubMed  CAS  Google Scholar 

  52. Ghany MG, Strader DB, Thomas DL, et al. American association for the study of liver diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374

    Article  PubMed  CAS  Google Scholar 

  53. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42:1109–1115

    Article  PubMed  CAS  Google Scholar 

  54. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008;48:1690–1699

    Article  PubMed  CAS  Google Scholar 

  55. Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J Viral Hepat 2001;8:287–292

    Article  PubMed  CAS  Google Scholar 

  56. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001;16:193–195

    Article  PubMed  CAS  Google Scholar 

  57. Mousa DH, Abdalla AH, Al-Shoail G, et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004;36:1831–1834

    Article  PubMed  CAS  Google Scholar 

  58. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alpha-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998;46:563–570

    Article  PubMed  CAS  Google Scholar 

  59. Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ 2006;29:1013–1017

    Article  Google Scholar 

  60. Mangia A, Burra P, Ciancio A, Italian Association for The Study of The Liver (AISF), et al. Hepatitis C infection in patients with chronic kidney disease. Int J Artif Organs 2008;31:15–33

    PubMed  CAS  Google Scholar 

  61. Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998;36:1711–1715

    PubMed  CAS  Google Scholar 

  62. Hanuka N, Sikuler E, Tovbin D, et al. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J Viral Hepat 2002;9:141–145

    Article  PubMed  CAS  Google Scholar 

  63. Dalekos GN, Boumba DS, Katopodis K, et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant 1998;13:1804–1806

    Article  PubMed  CAS  Google Scholar 

  64. Okuda K, Hayashi H, Yokozeki K, et al. Destruction of hepatitis C virus particles by haemodialysis. Lancet 1996;347:909–910

    Article  PubMed  CAS  Google Scholar 

  65. Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int 2005;9:169–179

    Article  PubMed  CAS  Google Scholar 

  66. Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008;18:97–115

    Article  PubMed  Google Scholar 

  67. Pawa S, Ehrinpreis M, Mutchnick M, et al. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007;5:1316–1320

    Article  PubMed  Google Scholar 

  68. Ozdogan M, Ozgur O, Boyacioplu S, et al. Percutaneous liver biopsy complications in patients with chronic renal failure. Nephron 1996;74:442–443

    Article  PubMed  CAS  Google Scholar 

  69. Ahmad A, Hasan F, Abdeen S, et al. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004;15:257–260

    Article  PubMed  Google Scholar 

  70. Poynard T, Imbert-Bismut F, Ratziu V, GERMED cyt04 group, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepatitis 2002;9:128–133

    Article  CAS  Google Scholar 

  71. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48–54

    Article  PubMed  Google Scholar 

  72. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589–2600

    Article  PubMed  Google Scholar 

  73. Varaut A, Fontaine H, Serpaggi J, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005;80:1550–1555

    Article  PubMed  Google Scholar 

  74. Cotler SJ, Diaz G, Diaz G. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002;35:191–195

    Article  PubMed  Google Scholar 

  75. Martin P, Carter D, Carter D. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000;69:1479–1484

    Article  PubMed  CAS  Google Scholar 

  76. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999;94:3576–3582

    Article  PubMed  CAS  Google Scholar 

  77. Di Napoli A, Pezzotti P, Di Lallo D, et al. Lazio Dialysis Registry Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006;48:629–637

    Article  PubMed  Google Scholar 

  78. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896–1902

    PubMed  CAS  Google Scholar 

  79. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 2003;14:3270–3277

    Article  PubMed  Google Scholar 

  80. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007;18:1584–1593

    Article  PubMed  Google Scholar 

  81. Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005;5:1452–1461

    Article  PubMed  CAS  Google Scholar 

  82. Roth D, Cirocco R, Reddy R. (2002) Ten year prospective study of hepatitis C virus infection in kidney transplant recipients. Am J Transpl 2:abstract no. 260A

  83. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998;66:471–476

    Article  PubMed  CAS  Google Scholar 

  84. Legendre CH, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C infection in kidney transplant recipients. Transplantation 1998;65:667–670

    Article  PubMed  CAS  Google Scholar 

  85. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257–263

    Article  PubMed  CAS  Google Scholar 

  86. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002;74:427–437

    Article  PubMed  CAS  Google Scholar 

  87. Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997;29:608–614

    Article  PubMed  CAS  Google Scholar 

  88. Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071–1081

    Article  PubMed  CAS  Google Scholar 

  89. Russo MW, Goldsweig CD, Jacobson IM, et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610–1615

    Article  PubMed  CAS  Google Scholar 

  90. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426–1432

    Article  PubMed  CAS  Google Scholar 

  91. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;19:1485–1492

    Article  Google Scholar 

  92. Fabrizi F, Dixit V, Messa P, et al. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008;15:79–88

    PubMed  CAS  Google Scholar 

  93. Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kid Dis 2010;4:181–194

    Google Scholar 

  94. Gordon CE, Uhlig K, Lau J, et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kid Dis 2008;51:263–277

    Article  PubMed  Google Scholar 

  95. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237–S244

    Article  PubMed  Google Scholar 

  96. Rocha CM, Perez RM, Ferreira AP, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006;26:305–310

    Article  PubMed  CAS  Google Scholar 

  97. Huraib S, Tanimu D, Romeh SA, et al. Interferon-α in chronic hepatitis C infection in dialysis patients. Am J Kid Dis 1999;34:55–60

    Article  PubMed  CAS  Google Scholar 

  98. Fernandez JL, Rendo P, Del Pino N. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepat 1997;4:113–119

    PubMed  CAS  Google Scholar 

  99. Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008;57:525–530

    Article  PubMed  CAS  Google Scholar 

  100. Ayaz C, Celen MK, Yuce UN, et al. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008;14:255–259

    Article  PubMed  CAS  Google Scholar 

  101. Casanovas-Taltavull T, Baliellas C, Llobet M, et al. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 2007;39:2125–2127

    Article  PubMed  CAS  Google Scholar 

  102. van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alpha-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008;23:721–725

    Article  PubMed  CAS  Google Scholar 

  103. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alpha-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:768–774

    Article  PubMed  CAS  Google Scholar 

  104. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19:17–24

    PubMed  CAS  Google Scholar 

  105. Mihm U, Herrmann E, Sarrazin C, et al. Review article: Predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006;23:1043–1054

    Article  PubMed  CAS  Google Scholar 

  106. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821–829

    Article  PubMed  Google Scholar 

  107. Degos F, Pol S. The tolerance and efficacy of interferon-α in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001;16:1017–1023

    Article  PubMed  CAS  Google Scholar 

  108. Hanrotel C, Toupance O, Toupance O. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001;88:120–126

    Article  PubMed  CAS  Google Scholar 

  109. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology 2006;130:1086–1097

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departamento de Clínica Médica da Disciplina de Moléstias Infecciosas, Grupo de Estudo das Hepatites Virais, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil

    Aline Gonzalez Vigani

  2. Hospital de Clínicas, Universidade Estadual de Campinas, PO Box 6198, Campinas, São Paulo, 13083-970, Brazil

    Aline Gonzalez Vigani

Authors
  1. Aline Gonzalez Vigani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aline Gonzalez Vigani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vigani, A.G. Hepatitis C infection and chronic renal diseases. Hepatol Int 7, 16–27 (2013). https://doi.org/10.1007/s12072-012-9356-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-012-9356-5

Keywords

Search

Navigation